Dr. Brant Inman is Chin-Hardie Chair of Urologic Oncology and Professor of Urology and Oncology at Western University (London, Canada), the London Health Sciences Center, and the Lawson Health Research Institute.

Dr. Inman received his Bachelor of Medical Science (1999) and MD (2000) degrees from the University of Alberta in Edmonton, Canada. He then completed his urology residency at l’Université Laval in Québec City, Canada (2005) and his urologic oncology fellowship at the Mayo Clinic in Rochester, USA (2008). He was on faculty at Duke University from 2008 to 2023 where he was the Cary N. Robertson Professor of Urology and Co-Director of the Prostate and Urologic Cancer Center of the Duke Cancer Institute. In September 2023 he joined the faculty at Western University where he presently holds the titles of Chin-Hardie Chair of Urologic Oncology,  Professor of Urology, and Professor of Oncology.

From a patient care standpoint, Dr. Inman’s medical practice is subspecialized in the field of urologic oncology. He treats patients with a variety of cancers of the genitourinary system including prostate cancer, bladder cancer, kidney cancer, ureter and renal pelvis cancer, testicular cancer, adrenal cancer, sarcomas, and penis cancer. He has a particular interest in inherited genetic syndromes that cause urological cancers and in complex cancers that require multi-disciplinary care. Dr. Inman performs surgery using a wide variety of methods including laparoscopic and robotic minimally invasive surgery, endoscopic surgery, and open surgery.

In addition to patient care, Dr. Inman is also heavily involved in research. His research interests are in the field of urologic oncology, including clinical trials and translational research related to bladder, prostate, and kidney cancer. He has worked on several types of projects including the development of new diagnostic tests for cancer, the development and testing of new treatments for cancer, understanding the immune response to cancer, and describing the genetic underpinnings of cancer. He is associate Editor of European Urology Focus. He has been a member of Board of Directors of the Society of Urologic Oncology Clinical Trials Consortium, a member of the National Comprehensive Cancer Network bladder and penile cancer panel, a member of the Research Council and Research Grants and Investigator Support Committee of the American Urological Association, and a member of the Urological Research Society.